Pharmacotherapeutic group: NSAID.
ATCvet code: QN02BA04
Pharmacodynamic properties
Sodium salicylate is a non-steroid anti-inflammatory drug (NSAID) and has an anti-inflammatory, analgesic and antipyretic effect. The mode of action is based on inhibition of the enzyme cyclooxygenase, resulting in decreased production of prostaglandin (inflammation mediators).
Pharmacokinetic properties
Orally administered sodium salicylate is rapidly absorbed by passive diffusion, partially from the stomach, but mainly from the anterior part of the small intestine. Sodium salicylate distributes very well to the various tissues. Values of volume of distribution (Vd) are higher in the newborns. Half-lives are longer in the very young resulting in slower elimination of the substance. This is most prominent in animals up to 7-14 days of age. Metabolism takes place mainly in the endoplasmatic reticulum and the mitochondria of the liver cells.
Elimination occurs mainly via the urine, and the pH of the urine can have a major effect on this elimination (see also Overdose).